Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - cisplatin - concentrate for solution for infusion - 1mg/1ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - cisplatin - concentrate for solution for infusion - 1mg/1ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - cisplatin - concentrate for solution for infusion - 1mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - mitoxantrone - concentrate for solution for infusion - 2 milligram(s)/millilitre - anthracyclines and related substances; mitoxantrone

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - docetaxel 20 mg/ml;   - concentrate for injection - 20 mg/ml - active: docetaxel 20 mg/ml   excipient: citric acid ethanol polysorbate 80 - breast cancer docetaxel accord is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel accord in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease. adjuvant treatment of breast cancer docetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel accord in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel accord in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel accord in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of greater than or equal to 1 cm and < 7 cm.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - etoposide, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: citric acid; ethanol; benzyl alcohol; macrogol 300; polysorbate 80 - small cell carcinoma of the lung. acute monocytic and myelomonocytic leukaemia; hodgkin's disease non-hodgkin's lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - etoposide, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: macrogol 300; benzyl alcohol; polysorbate 80; ethanol; citric acid - small cell carcinoma of the lung. acute monocytic and myelomonocytic leukaemia; hodgkin's disease non-hodgkin's lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - etoposide, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: citric acid; ethanol; macrogol 300; polysorbate 80; benzyl alcohol - small cell carcinoma of the lung. acute monocytic and myelomonocytic leukaemia; hodgkin's disease non-hodgkin's lymphoma.